ArticleJournal of psychopharmacology (Oxford, England)2022
Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample.
Article in Journal of psychopharmacology (Oxford, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Predictors of therapeutic response to psychedelic-assisted therapy: A systematic review.Journal of psychopharmacology (Oxford, England) · 2026Pooled it
- High ventilation breathwork as a non-pharmacological model for inducing psychedelic-like states: expert evaluations of therapeutic potential and risk.Npj mental health research · 2026Article
- Major life changes following psychedelic use: A retrospective survey among people using psychedelics naturalistically.Scientific reports · 2026Article
- Predictors of the Effectiveness of Psychedelics in Treating Depression-A Scoping Review.International journal of molecular sciences · 2026Article
- Naturalistic psychedelic use and changes in depressive symptoms.Journal of affective disorders · 2025Observational
- Naturalistic use of psychedelics is associated with longitudinal improvements in anxiety and depression during global crisis times.Journal of psychopharmacology (Oxford, England) · 2025Article
- Are "mystical experiences" essential for antidepressant actions of ketamine and the classic psychedelics?European archives of psychiatry and clinical neuroscience · 2025Review
- Psychedelics and chronic pain: self-reported outcomes on changed substance use patterns and health following naturalistic psychedelic use.British journal of pain · 2025Article
- Psychedelics for Depression: Between Hopes and Uncertainties.Focus (American Psychiatric Publishing) · 2025Article
- Naturalistic psychedelic experiences and gender-based self-acceptance in transgender and gender-expansive people.International journal of transgender health · 2025Article
- A prospective ecological momentary assessment study of an ayahuasca retreat: exploring the salutary impact of acute psychedelic experiences on subacute affect and mindfulness skills in daily life.Psychopharmacology · 2025Article
- Article
- Contextual and experiential aspects of the psychedelic experience predicting improvement in subjective wellbeing: results from a Norwegian internet convenience sample.Frontiers in pharmacology · 2025Article
- Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trial.Therapeutic advances in psychopharmacology · 2025Article
- Longitudinal associations between psychedelic use and psychotic symptoms in the United States and the United Kingdom.Journal of affective disorders · 2024Article
- Effects of DMT on mental health outcomes in healthy volunteers.Scientific reports · 2024Article
- Therapeutic mechanisms of psychedelics and entactogens.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Review
- Psychedelic substitution: altered substance use patterns following psychedelic use in a global survey.Frontiers in psychiatry · 2024Article
- Peer support and psychedelics.Journal of military, veteran and family health · 2023Article
- UNRAVELing the synergistic effects of psilocybin and environment on brain-wide immediate early gene expression in mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOver the last two decades, a number of studies have highlighted the potential of psychedelic therapy. However, questions remain to what extend these results translate to naturalistic samples, and how contextual factors and the acute psychedelic experience relate to improvements in affective symptoms following psychedelic experiences outside labs/clinics. The present study sought to address this knowledge gap.
aimHere, we aimed to investigate changes in anxiety and depression scores before versus after psychedelic experiences in naturalistic contexts, and how various pharmacological, extrapharmacological and experience factors related to outcomes.
methodIndividuals who planned to undergo a psychedelic experience were enrolled in this online survey study. Depressive symptoms were assessed at baseline and 2 and 4 weeks post-psychedelic experience, with self-rated Quick Inventory of Depressive Symptomatology (QIDS-SR-16) as the primary outcome. To facilitate clinical translation, only participants with depressive symptoms at baseline were included. Sample sizes for the four time points were
resultsRelative to baseline, reductions in depressive symptoms were observed at 2 and 4 weeks. A medicinal motive, previous psychedelic use, drug dose and the type of acute psychedelic experience (i.e. specifically, having an emotional breakthrough) were all significantly associated with changes in self-rated QIDS-SR-16.
conclusionThese results lend support to therapeutic potential of psychedelics and highlight the influence of pharmacological and non-pharmacological factors in determining response. Mindful of a potential sample and attrition bias, further controlled and observational longitudinal studies are needed to test the replicability of these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.